219 related articles for article (PubMed ID: 19001440)
1. Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide.
Hingtgen S; Ren X; Terwilliger E; Classon M; Weissleder R; Shah K
Mol Cancer Ther; 2008 Nov; 7(11):3575-85. PubMed ID: 19001440
[TBL] [Abstract][Full Text] [Related]
2. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
Kim SM; Woo JS; Jeong CH; Ryu CH; Jang JD; Jeun SS
Stem Cells Transl Med; 2014 Feb; 3(2):172-82. PubMed ID: 24436439
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma.
Jiang M; Liu Z; Xiang Y; Ma H; Liu S; Liu Y; Zheng D
BMC Cancer; 2011 Feb; 11():54. PubMed ID: 21291526
[TBL] [Abstract][Full Text] [Related]
4. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
[TBL] [Abstract][Full Text] [Related]
5. Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on temozolomide-resistant glioma cells.
Uzzaman M; Keller G; Germano IM
J Neurosurg; 2007 Apr; 106(4):646-51. PubMed ID: 17432717
[TBL] [Abstract][Full Text] [Related]
6. Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein.
Zhitao J; Long L; Jia L; Yunchao B; Anhua W
Tumour Biol; 2015 Dec; 36(12):9621-30. PubMed ID: 26142735
[TBL] [Abstract][Full Text] [Related]
7. Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas.
Germano IM; Emdad L; Qadeer ZA; Binello E; Uzzaman M
Cancer Gene Ther; 2010 Sep; 17(9):664-74. PubMed ID: 20523363
[TBL] [Abstract][Full Text] [Related]
8. Effective combination therapy for malignant glioma with TRAIL-secreting mesenchymal stem cells and lipoxygenase inhibitor MK886.
Kim SM; Woo JS; Jeong CH; Ryu CH; Lim JY; Jeun SS
Cancer Res; 2012 Sep; 72(18):4807-17. PubMed ID: 22962275
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma.
Wang Y; Huang F; Cai H; Wu Y; He G; Tan WS
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1827-37. PubMed ID: 20213096
[TBL] [Abstract][Full Text] [Related]
10. Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo.
Ulasov IV; Sonabend AM; Nandi S; Khramtsov A; Han Y; Lesniak MS
Br J Cancer; 2009 Apr; 100(7):1154-64. PubMed ID: 19277041
[TBL] [Abstract][Full Text] [Related]
11. In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.
Ashley DM; Riffkin CD; Lovric MM; Mikeska T; Dobrovic A; Maxwell JA; Friedman HS; Drummond KJ; Kaye AH; Gan HK; Johns TG; Hawkins CJ
Br J Cancer; 2008 Jul; 99(2):294-304. PubMed ID: 18594532
[TBL] [Abstract][Full Text] [Related]
12. Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide.
Weyhenmeyer BC; Noonan J; Würstle ML; Lincoln FA; Johnston G; Rehm M; Murphy BM
Oncotarget; 2016 Sep; 7(38):61295-61311. PubMed ID: 27494880
[TBL] [Abstract][Full Text] [Related]
13. Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model.
Saito R; Bringas JR; Panner A; Tamas M; Pieper RO; Berger MS; Bankiewicz KS
Cancer Res; 2004 Oct; 64(19):6858-62. PubMed ID: 15466173
[TBL] [Abstract][Full Text] [Related]
14. Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL.
Kock N; Kasmieh R; Weissleder R; Shah K
Neoplasia; 2007 May; 9(5):435-42. PubMed ID: 17534449
[TBL] [Abstract][Full Text] [Related]
15. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy.
Kim SM; Oh JH; Park SA; Ryu CH; Lim JY; Kim DS; Chang JW; Oh W; Jeun SS
Stem Cells; 2010 Dec; 28(12):2217-28. PubMed ID: 20945331
[TBL] [Abstract][Full Text] [Related]
16. Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy.
Yamini B; Yu X; Pytel P; Galanopoulos N; Rawlani V; Veerapong J; Bickenbach K; Weichselbaum RR
Clin Cancer Res; 2007 Oct; 13(20):6217-23. PubMed ID: 17947489
[TBL] [Abstract][Full Text] [Related]
17. Enhanced antitumor effect of combining interferon beta with TRAIL mediated by tumor-targeting adeno-associated virus vector on A549 lung cancer xenograft.
Wang Y; He L; He G; Kong Y; Liu X; Cai H; Liu X; Tan W
Sheng Wu Gong Cheng Xue Bao; 2010 Jun; 26(6):780-8. PubMed ID: 20815258
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5.
Fiveash JB; Gillespie GY; Oliver PG; Zhou T; Belenky ML; Buchsbaum DJ
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):507-16. PubMed ID: 18474311
[TBL] [Abstract][Full Text] [Related]
19. Combination treatment with VPA and MSCs‑TRAIL could increase anti‑tumor effects against intracranial glioma.
Park SA; Han HR; Ahn S; Ryu CH; Jeun SS
Oncol Rep; 2021 Mar; 45(3):869-878. PubMed ID: 33469674
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]